Worth reading
50Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
-15
¥100 million (year-on-year change in operating profit)Wording
Definitive
How definitive the wording is.Contents of this document
Presentation materials for financial resultsFiscal year ending March 20267 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales12,378 Hundreds of millions of yen+4.2%
Operating profit264 Hundreds of millions of yen-5.6%
Ordinary income298 Hundreds of millions of yen-5.9%
Net income220 Hundreds of millions of yen-3.6%
Gross Profit Margin7.46 %
Operating profit margin2.14 %
Selling, general and administrative expenses658 Hundreds of millions of yen
Results for the three months of the current quarter
Fourth quarter of the fiscal year ended March 2026
Net Sales
2,872 Hundreds of millions of yen
Gross profit
208 Hundreds of millions of yen
Operating profit
44 Hundreds of millions of yen
Ordinary income
52 Hundreds of millions of yen
Quarterly net income
47 Hundreds of millions of yen
Full-year earnings forecast
Net Sales
12,300 Hundreds of millions of yen
Gross profit
928 Hundreds of millions of yen
Selling, general and administrative expenses
638 Hundreds of millions of yen
Operating profit
290 Hundreds of millions of yen
Ordinary income
322 Hundreds of millions of yen
Net income for the current fiscal year
220 Hundreds of millions of yen
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Net sales achieved the plan; operating profit fell short of the planBreakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Increase in gross profit from higher revenue37 Hundreds of millions of yen
- Deterioration in the gross profit margin-3 Hundreds of millions of yen
- Increase in personnel expenses-16 Hundreds of millions of yen
- Increase in delivery costs-13 Hundreds of millions of yen
- Decline in Depreciation Expense0 Hundreds of millions of yen
- Increase in other SG&A expenses-19 Hundreds of millions of yen
New initiatives
- Capital investment in externally leased distribution centers
- Measures to secure logistics capacity over the medium to long term
Key KPIsA metric the company considers important as a management benchmark.
- Cosmetics net sales2,946 Hundreds of millions of yenYear on year against the same period last year+4.6%
- Daily necessities net sales5,564 Hundreds of millions of yenYear on year against the same period last year+5.9%
- Pharmaceuticals revenue1,445 Hundreds of millions of yenYear on year against the same period last year-2.4%
- Health and hygiene-related products net sales2,209 Hundreds of millions of yenYear on year against the same period last year+4.0%
- Net sales to drugstores8,039 Hundreds of millions of yenYear on year against the same period last year+5.3%
- Net sales to convenience stores1,162 Hundreds of millions of yenYear on year against the same period last year+8.0%
Unit price and quantity metricsThese figures show sales broken down by price and volume.
Selling prices increased across all categories, while selling volumes were described as sluggish; figures are Not disclosedCapital expenditures
26 Hundreds of millions of yen
Acquisition of treasury shares
41 Hundreds of millions of yen
| Item | Details |
|---|---|
| Document type | Presentation materials for financial results |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Net Sales | 12,378 Hundreds of millions of yen (YoY +4.2%) |
| Operating profit | 264 Hundreds of millions of yen (YoY -5.6%) |
| Ordinary income | 298 Hundreds of millions of yen (YoY -5.9%) |
| Net income | 220 Hundreds of millions of yen (YoY -3.6%) |
| Gross Profit Margin | 7.46 % |
| Operating profit margin | 2.14 % |
| Selling, general and administrative expenses | 658 Hundreds of millions of yen |
| Results for the three months of the current quarter | Subject Fourth quarter of the fiscal year ended March 2026 / Net Sales 2,872 Hundreds of millions of yen / Gross profit 208 Hundreds of millions of yen / Operating profit 44 Hundreds of millions of yen / Ordinary income 52 Hundreds of millions of yen / Quarterly net income 47 Hundreds of millions of yen |
| Full-year earnings forecast | Net Sales 12,300 Hundreds of millions of yen / Gross profit 928 Hundreds of millions of yen / Selling, general and administrative expenses 638 Hundreds of millions of yen / Operating profit 290 Hundreds of millions of yen / Ordinary income 322 Hundreds of millions of yen / Net income for the current fiscal year 220 Hundreds of millions of yen |
| Self-assessment against the plan | Net sales achieved the plan; operating profit fell short of the plan |
| Breakdown of Factors Affecting the Change | Factors Increase in gross profit from higher revenue / Amount 37 Hundreds of millions of yen, Factors Deterioration in the gross profit margin / Amount -3 Hundreds of millions of yen, Factors Increase in personnel expenses / Amount -16 Hundreds of millions of yen, Factors Increase in delivery costs / Amount -13 Hundreds of millions of yen, Factors Decline in Depreciation Expense / Amount 0 Hundreds of millions of yen, Factors Increase in other SG&A expenses / Amount -19 Hundreds of millions of yen |
| Key KPIs | Indicator name Cosmetics net sales / Value 2,946 Hundreds of millions of yen / Year on year against the same period last year 4.6 Hundreds of millions of yen, Indicator name Daily necessities net sales / Value 5,564 Hundreds of millions of yen / Year on year against the same period last year 5.9 Hundreds of millions of yen, Indicator name Pharmaceuticals revenue / Value 1,445 Hundreds of millions of yen / Year on year against the same period last year -2.4 Hundreds of millions of yen, Indicator name Health and hygiene-related products net sales / Value 2,209 Hundreds of millions of yen / Year on year against the same period last year 4 Hundreds of millions of yen, Indicator name Net sales to drugstores / Value 8,039 Hundreds of millions of yen / Year on year against the same period last year 5.3 Hundreds of millions of yen, Indicator name Net sales to convenience stores / Value 1,162 Hundreds of millions of yen / Year on year against the same period last year 8 Hundreds of millions of yen |
| Unit price and quantity metrics | Selling prices increased across all categories, while selling volumes were described as sluggish; figures are Not disclosed |
| Acquisition of treasury shares | Amount 41 Hundreds of millions of yen |
| Capital expenditures | 26 Hundreds of millions of yen |
| New initiatives | Capital investment in externally leased distribution centers, Measures to secure logistics capacity over the medium to long term |
Items this document does not state (13)
Progress against full-year forecastSegment resultsNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Net sales benefited from winning new account business, expanding the range of products handled, growth in products related to going out and health foods, price increases, and increased sales of high-value-added products. Operating profit was affected by a decline in the gross profit margin, as well as increases in personnel expenses, delivery costs, warehouse labor costs, expenses for externally leased distribution centers and other SG&A expenses.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.